Search Results
Jan 06, 2026, 09:00 ET Hesai Selected by NVIDIA as Lidar Partner for NVIDIA DRIVE Hyperion 10 to Enable Level 4 Fleet Deployment
DRIVE AGX Thor systems-on-a-chip built on the NVIDIA Blackwell architecture, DRIVE Hyperion delivers more than 2,000 FP4 teraflops — or roughly 1,000 INT8 trillion operations per second — of real‑time compute to fuse a full 360‑degree sensor view."Everything that moves will eventually become autonomous,
More news about: Hesai Technology
Jan 05, 2026, 06:30 ET MulticoreWare Demonstrates Real-Time Cloud-to-Car AI Workflow with Qualcomm AI HUB and QCR100 Instance at CES 2026
Hub & MulticoreWare Workflow for OEMsSeamless Model Optimization: Smooth transition from FP32 to quantized INT8/INT16 models.Scalable Cloud Workflow: On-demand access to QCR100 instances for global validation and CI/CD pipelines without on-premises
More news about: MulticoreWare Inc.
Dec 25, 2025, 21:29 ET 青島自由貿易区：生命健康産業は「ビーズ」を連ねて「チェーン」になる
青島（中国）、2025年12月26日 /PRNewswire/ -- Chengda Int. Mediaより：世界初の免疫抗腫瘍海洋糖類新薬であるBG136が2期治験を順調に推進している。同薬は、青島国信製薬が中国海洋大学等と共同で開発し、南極褐藻を原料とし、進行性固形腫瘍の治療に用いられ、2028年に条件付きで発売される見込みである。これは青島自由貿易区の生命健康産業のステップアップの生き生きとした縮図である。青島の遺伝子と細胞産業の資源集中区として、青島自由貿易区（中徳生態園）は政策上のサポートを継続的に強化し、生命健康産業プロジェクトを62件集積し、省レベル以上の
More news about: CHENGDA(QINGDAO) INTERNATIONAL MEDIA CO.,LTD.
Dec 25, 2025, 01:39 ET 中国の青島：5年間で1兆7000億元までまい進し、発展の新たなベンチマークを鋳造
青島（中国）、2025年12月25日 /PRNewswire/ -- Chengda Int. Mediaより： 青島市が最新発表したデータによると、過去5年間で全市の地域総生産（GDP）は連続5段で千億元レベルの階段を跨い、2025年には歴史的に1兆7000億元を突破する見通しである。この飛躍は、青島の都市機能レベルの実質的な飛躍を示しているだけでなく、年平均5.9%の着実な成長率も複雑で変化に富んだ経済環境の下での青島の強大な靭性と澎湃たる活力を更に示している。●革新で駆動し、質の高い発展の「強いエ
More news about: CHENGDA(QINGDAO) INTERNATIONAL MEDIA CO.,LTD.
Dec 22, 2025, 05:00 ET ez1099 Now Offers Electronic Filing Service, Add-On Feature!
submissionsComprehensive Form Support:2025 Form 1099 Series: 1099-A, 1099-B, 1099-C, 1099-CAP, 1099-DA, 1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB,2025 Form 1098 Series:
More news about: Halfpricesoft.com
Dec 19, 2025, 09:00 ET Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial
November 2025 3 Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–11924 Olmos, D. et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer
More news about: TOLMAR
Dec 17, 2025, 16:05 ET Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
Linear and Area Coverage with Closed Incision Negative Pressure Therapy Management: International Multidisciplinary Consensus Recommendations. Int Wound J. 2025;22:e7067.3 Cooper HJ, Singh DP, Gabriel A, Mantyh C, Silverman R, Griffin L. Closed Incision Negative Pressure
More news about: Solventum
Dec 12, 2025, 08:12 ET Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
here.ReferencesSmith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143.Servais A, et al. Kidney Int. 2012;82(4):454-464.Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.Tarragón, B, et al. C3 Glomerulopathy Recurs Early after
More news about: Swedish Orphan Biovitrum AB
Dec 12, 2025, 05:00 ET ez1099 2025 Has Been Enhanced with a New Electronic Filing Service!
20252025 Form 1099 Series - including 1099-A, 1099-B, 1099-C,1099-CAP, 1099-D1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB)2025 Form 1098
More news about: Halfpricesoft.com
Dec 11, 2025, 07:47 ET Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
still seek full approval using event free survival as an endpoint.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Dec 09, 2025, 19:26 ET Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
References[1]. J Transl Int Med. 2022;10(2):134-145[2].
More news about: Innovent Biologics
Dec 08, 2025, 14:00 ET Tiger BioSciences Highlights Study on Advanced Placental CAMP Technologies
P.; Guha, S.; Landa, O.; King, A.R.; Valdes Cavazos, D.; Marquez, J.; Hill, S. Native Wound-Repair Proteins Retained in Multilayer Placental CAMPs. Int. J. Mol. Sci. 2025, 26, 10121.
More news about: Tiger BioSciences
Dec 08, 2025, 08:30 ET Primis Financial Corp. Announces Sale-Leaseback Transaction
0.0 %Non-int Income11,969
More news about: Primis Financial Corp.
Dec 05, 2025, 07:30 ET Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
www.intensitytherapeutics.com. About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Dec 04, 2025, 11:00 ET Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
ivJäger R, et al. J Int Soc Sports Nutr. 2017;14:20.v
More news about: Abbott
Dec 04, 2025, 09:00 ET Armada Participates in U.S. Navy UNITAS Exercise, Delivering Power, Data, and Resilience in Disconnected Environments
Edge servers to provide a secure, resilient hybrid cloud environment with enterprise services, as well as Minotaur operator workload, ingesting multi-INT data from multiple robotic autonomous systems (RASs) and other sources. The Galleon also successfully redeployed for ship-based testing with its flexible
More news about: Armada
Dec 04, 2025, 07:47 ET Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Müller, M.D., Swiss Cancer InstituteAbout INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
Dec 04, 2025, 02:39 ET The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN
Data on file using literature consensus. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. Servais A, et al. Kidney Int. 2012;82(4):454-464. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117. Tarragón, B, et al. C3 Glomerulopathy Recurs Early
More news about: Swedish Orphan Biovitrum AB
Dec 03, 2025, 18:10 ET Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Dec 02, 2025, 16:40 ET New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Horie et al., CSF MTBR-tau243 is a specific biomarker
More news about: Eisai Inc.
Nov 28, 2025, 20:00 ET SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
nodes.The mission supports broader international efforts to establish quantum-secure communication networks, including the European Space Agency's INT-UQKD and Q-DESIGN programmes, highlighting global recognition of quantum communications as critical technology for future cybersecurity.Singapore-UK
More news about: SpeQtral
Nov 25, 2025, 07:30 ET Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway
More news about: Eisai Inc.
Nov 21, 2025, 04:00 ET ez1099 2025 Launches, Making Tax Season Effortless for Accountants and SMBs
users."Built for efficiency and accuracy, ez1099 offers:Easy setup and form preparation for 1099-MISC, 1099-NEC, 1099-INT, 1099-DIV, 1098, and moreThe ability to print forms on plain white paper—no red ink forms requiredSecure import, data review, and e-filing
More news about: Halfpricesoft.com
Nov 18, 2025, 08:00 ET Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
10.1038/s41467-021-23507-z.2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
More news about: Eisai Inc.
Nov 17, 2025, 11:19 ET BGN Announces Strategic MOU with XCF Global to produce and supply Sustainable Aviation Fuel
HOUSTON, Nov. 17, 2025 /PRNewswire/ -- BGN INT US LLC ("BGN"), an independent global energy and commodities group and a market leader in transition fuels has signed a Memorandum of Understanding
More news about: BGN